Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Urol. Nov 24, 2014; 3(3): 168-183
Published online Nov 24, 2014. doi: 10.5410/wjcu.v3.i3.168
Published online Nov 24, 2014. doi: 10.5410/wjcu.v3.i3.168
Metabolic syndrome in the development and progression of prostate cancer
Andrew C Strine, Kevin R Rice, Timothy A Masterson, Department of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, United States
Author contributions: Strine AC, Rice KR and Masterson TA contributed to this work; Strine AC wrote this manuscript.
Correspondence to: Andrew C Strine, MD, Department of Urology, Indiana University School of Medicine, 535 N. Barnhill Drive, Suite 150, Indianapolis, IN 46202, United States. astrine@iupui.edu
Telephone: +1-317-9487560 Fax: +1-317-9440174
Received: March 9, 2014
Revised: June 12, 2014
Accepted: July 12, 2014
Published online: November 24, 2014
Processing time: 255 Days and 12.3 Hours
Revised: June 12, 2014
Accepted: July 12, 2014
Published online: November 24, 2014
Processing time: 255 Days and 12.3 Hours
Core Tip
Core tip: The current literature is conflicted on the association between metabolic syndrome (MetS) and prostate cancer (PCa), although several studies have demonstrated that men with MetS or its individual components may have an increased risk of more aggressive disease and mortality as well as a poorer outcome after their treatment for PCa. These men may benefit from weight loss, physical activity, and the addition of medications like statins for preventing PCa and improving their outcomes after treatment. A majority of the existing evidence is retrospective or observational in nature, which underscores the need for more randomized controlled trials in the future.